Status:
COMPLETED
The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment
Lead Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Conditions:
Hearing Loss
Cytomegalovirus
Eligibility:
All Genders
Up to 21 years
Brief Summary
This study will look at the feasibility and acceptability of testing newborn babies who are referred after their newborn hearing screen for an infection called congenital Cytomegalovirus (cCMV). Aroun...
Eligibility Criteria
Inclusion
- All infants 'referred' for one or both ears following hospital-based newborn hearing screening in North of Tyne and South West London areas. Babies with other known causes of SNHL (e.g. hereditary) and those admitted to Neonatal Intensive Care Units will be included.
Exclusion
- Exclusions to this study will be infants with parents/guardians not willing/able to give informed consent or children known to have congenital CMV by antenatal testing or clinical features of CMV infection at birth.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
411 Patients enrolled
Trial Details
Trial ID
NCT01162330
Start Date
August 1 2010
End Date
February 1 2013
Last Update
October 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Victoria Infirmary, Newcastle Hospital NHS Trust
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP